The Effect of Semaglutide on Cardiovascular Markers and Liver Function
NCT06301191
·
clinicaltrials.gov ↗
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Diabetes Type 2
Interventions
DRUG:
Semaglutide, 1.0 mg/mL
DRUG:
Dipeptidyl Peptidase 4 inhibitor
Sponsor
Attikon Hospital